Graf Akcie LXRX (Lexicon Pharmaceuticals Inc). Diskuze k akciím LXRX. Aktuální informace LXRX.

Základní informace o společnosti Lexicon Pharmaceuticals Inc (Akcie LXRX)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 883.65M
Hodnota podniku (EV) 570.76M
Tržby 7.094M
EBITDA -90.96
Zisk 38.083M
Růst v tržbách Q/Q -97.45 %
Růst v tržbách Y/Y -97.79 %
P/E (Cena vůči ziskům) 13.39
Forward P/E -24.88
EV/Sales 80.46
EV/EBITDA N/A
EV/EBIT 13.36
PEG N/A
Price/Sales 124.56
P/FCF N/A
Price/Book 5.65
Účetní hodnota na akcii 1.09
Hotovost na akcii 1.06
FCF vůči ceně -12.64 %
Počet zaměstnanců 78
Tržba na zaměstnance 90.949k
Profit margin -244.11 %
Operating margin 569.76 %
Gross margin 91.96 %
EBIT margin 602.02 %
EBITDA margin -1,282.20 %
EPS - Zisk na akcii 0.46
EPS - Kvartální růst -80.00 %
EPS - Očekávaný růst příští rok -122.54 %
Return on assets 20.37 %
Return on equity 28.54 %
ROIC -14.17 %
ROCE 30.76 %
Dluhy/Equity 0.30
Čistý dluh/EBITDA 5.15
Current ratio 3.76
Quick Ratio 3.76
Volatilita 5.03
Beta 0.00
RSI 73.61
Cílová cena analytiků 2
Známka akcie (dle analytiků) 2.67
Insider ownership 4.18 %
Institutional ownership 84.95 %
Počet akcií 144.474M
Procento shortovaných akcií 5.41 %
Short ratio 6.00 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 2000
Země United States

Finanční výsledky akcie LXRX

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$322.073$63.209$91.689$79.256$130.014$22.854
Cost Of Goods Sold$3.231$2.491$1.899---
Gross Profit$318.842$60.718$89.79$79.256$130.014$22.854
Research And Development Expenses$91.924$100.243$152.223$163.973$95.187$89.279
SG&A Expenses$56.835$63.754$66.09$43.157$23.835$19.411
Other Operating Income Or Expenses$-28.638---$-3.597$-13.102
Operating Expenses$180.628$166.488$222.313$206.427$128.546$123.22
Operating Income$141.445$-103.279$-130.624$-127.171$1.468$-100.366
Total Non-Operating Income/Expense$-17.326$-17.269$-5.03$-4.274$-6.15$0.002
Pre-Tax Income$124.119$-120.548$-135.654$-131.445$-4.682$-100.364
Income Taxes$-6.014-$-12.661---
Income After Taxes$130.133$-120.548$-122.993$-131.445$-4.682$-100.364
Other Income------
Income From Continuous Operations$130.133$-120.548$-122.993$-131.445$-4.682$-100.364
Income From Discontinued Operations------
Net Income$130.133$-120.548$-122.993$-131.445$-4.682$-100.364
EBITDA$175.202$-98.26$-126.626$-124.588$2.715$-98.338
EBIT$141.445$-103.279$-130.624$-127.171$1.468$-100.366
Basic Shares Outstanding10610610510410476
Shares Outstanding11710610510410476
Basic EPS$1.23$-1.14$-1.17$-1.27$-0.05$-1.31
EPS - Earnings Per Share$1.16$-1.14$-1.17$-1.27$-0.05$-1.31
# 2020 2019 2018 2017 2016 2015
Current Ratio5.16914.71623.05242.17364.338.2054
Long-term Debt / Capital0.66661.12140.77230.35110.2610.2355
Debt/Equity Ratio2.0938-9.27863.59880.64450.36010.3791
Gross Margin98.996896.059197.9289100100100
Operating Margin43.9171-163.3929-142.4642-160.4561.1291-439.1616
EBIT Margin43.9171-163.3929-142.4642-160.4561.1291-439.1616
EBITDA Margin54.3982-155.4525-138.1038-157.19692.0883-430.2879
Pre-Tax Profit Margin38.5375-190.7133-147.9501-165.8487-3.6012-439.1529
Net Profit Margin40.4048-190.7133-134.1415-165.8487-3.6012-439.1529
Asset Turnover0.7710.22250.210.16660.19940.0485
Inventory Turnover Ratio0.76150.53230.9748---
Receiveable Turnover5.697210.6719.002910.5788142.715722.0812
Days Sales In Receivables64.066834.208119.207634.50312.557516.5299
ROE - Return On Equity111.1289456.5332-180.17-83.5097-1.6379-35.3372
Return On Tangible Equity246.268299.5713436.7188-220.9122-2.4911-53.9249
ROA - Return On Assets31.1535-42.4262-28.1746-27.6363-0.7181-21.2917
ROI - Return On Investment37.0462-55.429-41.0194-54.1889-1.2104-27.0146
Book Value Per Share1.1019-0.24930.64651.50952.75862.7447
Operating Cash Flow Per Share2.3790.3575-0.0707-3.47472.77420.252
Free Cash Flow Per Share2.37930.3587-0.0706-3.47142.74130.3011